Additionally, the exclusion of patients with known CAD, prior STEMI, a history of coronary intervention or bypass grafting, known congestive heart failure and/or severe valvular disease, renal failure, autoimmune disease, systemic inflammatory conditions, cancer, haematological disorders, acute or chronic infection of any organ system and any drug therapy that may affect the measurement of azurocidin, may have limited the generalizability of the results. This evidence concerns the gene AZU1 and hematologic disorder.